XML 61 R45.htm IDEA: XBRL DOCUMENT v3.25.1
ORGANIZATION AND NATURE OF THE BUSINESS (Details Narrative) - USD ($)
1 Months Ended 12 Months Ended
Apr. 03, 2023
Jan. 06, 2023
Jan. 23, 2024
Jun. 30, 2023
Jun. 15, 2023
Apr. 24, 2023
Feb. 28, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Stockholders' equity               $ 24,532,929 $ 36,043,028 $ 39,284,295
Accumulated deficit               (114,022,275) (91,644,233)  
Working capital               (296,193)    
Revenue               54,426,402 53,376,874  
Net loss               (16,183,018) (18,542,654)  
Net cash used in operations               7,717,034    
Impairment charge               291,980 0  
Building Acquision [Member]                    
Cash   $ 3,950,000       $ 1,054,872        
Equity method investment aggregate cost               2,000,020    
Greece [Member]                    
Revenue               52,935,979 $ 50,526,307  
Cash         $ 109,330          
Intangible assets         425,411          
Issuable stock amount         $ 316,081          
Shares issued         99,710          
CANA Pharmaceutical Laboratories, S.A. ("Cana") [Member]                    
Cash       $ 873,600            
Issuable stock amount       $ 138,667       138,667    
Shares issued       46,377            
Asset acquision             $ 5,469,787      
Secured Promissory Note             $ 4,457,520      
Zip Doctor Inc [Member]                    
Cash $ 150,000                  
Payment of fees 8,788                  
Intangible assets $ 158,788                  
Impairment charge               $ 131,032    
Cloudscreen [Member]                    
Cash     $ 317,880              
Total purchase price amount     $ 637,080              
Shares of common stock issued     280,000              
Shares of common fair value     $ 319,200              
Asset acquisition     $ 637,080